ADVANCE THE DEVELOPMENT OF PAAG17G (DRUG PRODUCT: MIIST305), A ONCE DAILY, ORALLY ADMINISTERED, GUT-RESTRICTED DRUG, TO REDUCE MORTALITY AND MORBIDITY ARISING FROM ACUTE EXPOSURE TO IONIZING RADIATION, SPECIFICALLY GASTROINTESTINAL (GI) INJURY (GI-AR
$18,828,663
| Recipient | SYNEDGEN, INC. UEI HX79BD6YQ521 |
|---|---|
| Award ID | 75A50124C00047 |
| Award amount | $18,828,663 |
| Award type | DEFINITIVE CONTRACT |
| Awarding agency | Department of Health and Human Services — Office of Assistant Secretary for Preparedness and Response |
| NAICS | 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) |
| PSC | AN13 |
| Start date | Sep 30, 2024 |
| End date | Aug 18, 2025 |
| Place of performance | CLAREMONT, CA |
| Record updated | May 27, 2026 |
View the official award record
More awards won by SYNEDGEN, INC.
SBIR PHASE III PROPOSAL NO. JW230017 TITLED, "OPTIMIZED, FIELD-STABLE GLYCOPOLYMER-MIMICKING POLYSACCHARIDE TO PREVENT MORBIDITY AND MORTALITY IN EXPOSURE TO IONIZING RADIATION OR NUCLEAR INJURY"
Department of Defense · $2,297,415 · Sep 20, 2024
AWARD OF SYNEDGEN'S DHA SBIR PHASE III FOLLOW-ON MEDICAL R&D CONTRACT FOR "DEVELOPMENT OF TECHNOLOGIES THAT CONTROL SCAR FORMATION AFTER BURN INJURIES"
Department of Defense · $549,725 · Aug 22, 2022
Our catalog shows awards of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.
Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. Free for 14 days, then $49.99/month.
Search open bids